News
JHPCY
15.64
NaN%
--
Braveheart, Attovia, Apnimed join gene therapy firm Scribe in July IPO rush
Seeking Alpha · 07/15 18:38
Kailera falls after late-stage trial data for oral GLP-1 candidate
Seeking Alpha · 07/07 15:41
Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle
Seeking Alpha · 05/27 14:09
Bristol Myers and China’s Hengrui Pharma ink a licensing deal worth up to $15.2B
Seeking Alpha · 05/12 12:03
Weight loss drug developer Kailera climbs 50% on trading debut
Seeking Alpha · 04/17 17:58
Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results
Seeking Alpha · 04/06 17:20
GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs
Seeking Alpha · 03/28 13:50
Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly's orforglipron
Seeking Alpha · 02/10 20:17
More
Webull provides a variety of real-time JHPCY stock news. You can receive the latest news about Jiangsu Hengrui Medicine Co Lt through multiple platforms. This information may help you make smarter investment decisions.
About JHPCY
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of drugs. The Company focuses on the field of oncology, covering kinase inhibitors, antibody-drug conjugates (ADCs), tumor immunity, hormone receptor regulation, deoxyribonucleic acid (DNA) repair and epigenetics, supportive care and other research areas. The Company's products include anti-tumor, analgesic anesthesia and contrast agents, which are used in autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, blood diseases, pain management, neurological diseases, ophthalmology, nephrology and other fields. The Company mainly conducts its businesses in domestic and foreign markets.